SIRS peptide – oral therapeutic for Multiple Sclerosis and Type I Diabetes

### Advantages of oral therapy for human inflammatory diseases

Administration of immunoactive protein therapeutics orally is advantageous to traditional parenteral administration:
- ease of delivery
- patient convenience
- tolerance
- cost effectiveness
- favorable therapeutic index

### Dr. Brod’s research and clinical work:

Dr. Brod has translated the concept of oral therapy (ingested type I IFN) from animal models into patient-oriented research in human inflammatory diseases, in particular Multiple Sclerosis, type 1 diabetes and Alzheimer’s Disease. Investigator-initiated phase I-II clinical trials for these indications have resulted from his basic science discoveries.

### SIRS Peptide for Treating of Autoimmune Diseases

Our patent applications (US11/570221 - EP05758009.4 - CA2568384) cover methods of using soluble immune response suppressor (SIRS) in the treatment of autoimmune diseases, such as multiple sclerosis and type 1 diabetes. We have completed animal testing for MS and Type I Diabetes and are seeking a commercial partner to pursue preclinical and clinical development of this biopharmaceutical product candidate.

40% of multiple sclerosis patients are non-responders to parenteral type I IFN. Since SIRS is endogenously produced downstream to interaction of IFN with the interferon-α/β receptor (IFNAR), SIRS should be therapeutically potent in IFN-resistant patients because it bypasses the submaximal IFN-IFNAR interaction. To increase the proportion of responding patients, combination of oral SIRS with oral or injected IFN-alpha would provide an additional therapeutic benefit.

Ingested (oral) SIRS peptide 1-21 inhibits acute EAE by inducing Th2-like cytokines

Ingested (oral) SIRS peptide 1-21 suppresses type 1 diabetes in NOD mice


Clayton Biotechnologies, Inc. wishes to license this patent portfolio. For more information, please contact our business development unit:

Dr. Alexandra Richardson +41-22-382-3802 - arichardson@claytonbiotech.com

©2009 Clayton Biotechnologies Inc – www.claytonbiotech.com